Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 18.30
LIFE's Cash to Debt is ranked lower than
53% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. LIFE: 18.30 )
Ranked among companies with meaningful Cash to Debt only.
LIFE' s Cash to Debt Range Over the Past 10 Years
Min: 1.54  Med: 5008.65 Max: N/A
Current: 18.3
Z-Score: 4.73
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
ROE (%) -106.98
LIFE's ROE (%) is ranked lower than
83% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. LIFE: -106.98 )
Ranked among companies with meaningful ROE (%) only.
LIFE' s ROE (%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: -106.98
ROA (%) -50.02
LIFE's ROA (%) is ranked lower than
68% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. LIFE: -50.02 )
Ranked among companies with meaningful ROA (%) only.
LIFE' s ROA (%) Range Over the Past 10 Years
Min: -80.59  Med: -80.59 Max: -80.59
Current: -50.02
ROC (Joel Greenblatt) (%) -2436.28
LIFE's ROC (Joel Greenblatt) (%) is ranked lower than
72% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. LIFE: -2436.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LIFE' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2447.17  Med: -2447.17 Max: -2447.17
Current: -2436.28
» LIFE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

LIFE Guru Trades in

Q2 2015

LIFE Guru Trades in Q2 2015

RS Investment Management 669,237 sh (New)
» More
Q3 2015

LIFE Guru Trades in Q3 2015

RS Investment Management 1,082,249 sh (+61.71%)
» More
Q4 2015

LIFE Guru Trades in Q4 2015

RS Investment Management 1,206,249 sh (+11.46%)
» More
» Details

Insider Trades

Latest Guru Trades with LIFE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on aTyr Pharma Inc

Mario Gabelli Comments on Life Technologies Corp - Apr 30, 2014

Life Technologies Corp. (LIFE) is a California based biotechnology company focused on reagents and scientific instruments. On April 15, 2013, Thermo Fisher Scientific announced it would acquire Life for $76 cash per share in a $13.6 billion merger. Shareholders approved the deal in August of 2013 and the merger was completed on February 3, 2014, after regulators in the U.S., European Union, and China approved it. As part of the merger agreement, the Fund received an incremental $0.13 per share in the form of a ticking fee, since the deal did not close by January 14, 2014. The Fund's return was 5.92%.

From Mario Gabelli (Trades, Portfolio)'s first quarter 2014 ABC Fund commentary.

Check out Mario Gabelli latest stock trades

Ratios

vs
industry
vs
history
P/B 0.76
LIFE's P/B is ranked higher than
93% of the 1128 Companies
in the Global Biotechnology industry.

( Industry Median: 2.66 vs. LIFE: 0.76 )
Ranked among companies with meaningful P/B only.
LIFE' s P/B Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 42.54
Current: 0.76
0
42.54
EV-to-EBIT 0.02
LIFE's EV-to-EBIT is ranked higher than
100% of the 449 Companies
in the Global Biotechnology industry.

( Industry Median: 18.07 vs. LIFE: 0.02 )
Ranked among companies with meaningful EV-to-EBIT only.
LIFE' s EV-to-EBIT Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.06
Current: 0.02
0
0.06
EV-to-EBITDA 0.02
LIFE's EV-to-EBITDA is ranked higher than
100% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 15.20 vs. LIFE: 0.02 )
Ranked among companies with meaningful EV-to-EBITDA only.
LIFE' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0.06
Current: 0.02
0
0.06
Current Ratio 12.69
LIFE's Current Ratio is ranked higher than
81% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. LIFE: 12.69 )
Ranked among companies with meaningful Current Ratio only.
LIFE' s Current Ratio Range Over the Past 10 Years
Min: 1.69  Med: 8.06 Max: 12.69
Current: 12.69
1.69
12.69
Quick Ratio 12.69
LIFE's Quick Ratio is ranked higher than
82% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. LIFE: 12.69 )
Ranked among companies with meaningful Quick Ratio only.
LIFE' s Quick Ratio Range Over the Past 10 Years
Min: 1.69  Med: 8.06 Max: 12.69
Current: 12.69
1.69
12.69

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.00
LIFE's Price/Net Cash is ranked higher than
93% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: 5.67 vs. LIFE: 1.00 )
Ranked among companies with meaningful Price/Net Cash only.
LIFE' s Price/Net Cash Range Over the Past 10 Years
Min: 2.51  Med: 3.71 Max: 4.9
Current: 1
2.51
4.9
Price/Net Current Asset Value 0.98
LIFE's Price/Net Current Asset Value is ranked higher than
93% of the 883 Companies
in the Global Biotechnology industry.

( Industry Median: 5.05 vs. LIFE: 0.98 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LIFE' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.45  Med: 3.60 Max: 4.74
Current: 0.98
2.45
4.74
Price/Tangible Book 0.75
LIFE's Price/Tangible Book is ranked higher than
95% of the 1034 Companies
in the Global Biotechnology industry.

( Industry Median: 9.50 vs. LIFE: 0.75 )
Ranked among companies with meaningful Price/Tangible Book only.
LIFE' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.88  Med: 2.51 Max: 3.14
Current: 0.75
1.88
3.14
Earnings Yield (Greenblatt) (%) 3320.68
LIFE's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. LIFE: 3320.68 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LIFE' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1313.04  Med: 0.00 Max: 5952.63
Current: 3320.68
-1313.04
5952.63

More Statistics

Revenue(Mil) $3799
EPS $ -1.22
Short Percentage of Float4.56%
52-Week Range $3.55 - 28.29
Shares Outstanding(Mil)23.65

Business Description

Industry: Biotechnology » Biotechnology
Compare:LH, ALR, DGX, ENZ, IDXX » details
aTyr Pharma Inc was incorporated in the state of Delaware on September 8, 2005. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. It has discovered approximately 300 Physiocrines, a class of naturally occurring human proteins that it promotes homeostasis, a fundamental process of restoring stressed or diseased tissue to a healthier state. The Company is currently conducting a multi-national exploratory Phase 1b/2 clinical trial of Resolaris in adult patients with FSHD in the European Union. This randomized, double-blind, placebo-controlled trial is designed to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple intravenous doses of Resolaris in adults with FSHD. Its initial therapeutic efforts target severe, rare disease indications in which patients suffer from the immune-related consequences of their genetic disease. It contracts with third parties for the manufacturing and testing of its product candidates for preclinical studies and clinical trials and intend to do so in the future. It does not own or operate manufacturing facilities for the production of clinical quantities of its product candidates. Government authorities in the United States, including federal, state, and local authorities, and in other countries, extensively regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and reporting, advertising and promotion, pricing, and export and import of pharmaceutical and biological products, such as those it is developing.
» More Articles for LIFE

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements... Jan 29 2016
CryoLife Completes Acquisition of On-X Life Technologies Holdings, Inc. Jan 20 2016
ATYR PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jan 11 2016
aTyr Provides Corporate Update And Outlook For 2016 Jan 11 2016
aTyr Provides Corporate Update And Outlook For 2016 Jan 11 2016
aTyr Pharma to Present at 34th Annual J.P. Morgan Healthcare Conference Jan 07 2016
aTyr Pharma to Present at 34th Annual J.P. Morgan Healthcare Conference Jan 07 2016
aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer Jan 06 2016
aTyr Pharma Appoints Sanuj Ravindran, M.D., as Chief Business Officer Jan 06 2016
ATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers Dec 28 2015
aTyr Pharma (LIFE) Jumps: Stock Moves 18.8% Higher Dec 18 2015
aTyr Pharma Added to NASDAQ Biotechnology Index Dec 16 2015
aTyr Pharma Added to NASDAQ Biotechnology Index Dec 16 2015
aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process... Dec 09 2015
aTyr Pharma to Host Breakout Session at the 6th Annual World Orphan Drug Congress Dec 09 2015
aTyr Pharma Announces Third Quarter 2015 Operating Results Dec 09 2015
Is aTyr Pharma Inc (LIFE) A Good Stock To Buy? Dec 09 2015
aTyr Pharma Selects Second IND Candidate, The First Engineered Physiocrine for GMP Process... Nov 11 2015
ATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 10 2015
aTyr Pharma Announces Third Quarter 2015 Operating Results Nov 10 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK